The Global Small Animal Imaging In Vivo Market Size is valued at 2.36 billion in 2022 and is predicted to reach 5.11 billion by the year 2031 at a 9.16% CAGR during the forecast period for 2023-2031.
As technology continues to advance, multimodal instruments are being developed and used at a rapid rate in both preclinical and clinical settings. In addition, SPECT/CT scanners are increasingly frequently utilized for regular analysis. Dual-modality or hybrid PET/CT scanners are favored systems for clinical nuclear medicine. These multimodal devices benefit from combining the functional strength of one technology, such SPECT and PET, with the high-resolution anatomical imaging provided by CT or MRI.
Recent improvements in preclinical in-vivo modalities include PET/CT, PET/MRI, and SPECT/CT. The development of the market is greatly influenced by technological improvements. The M2 3D MR-based histology system, for example, was introduced by Aspect Imaging for in-vivo and ex-vivo toxicological imaging.
For high-throughput in-vivo and ex-vivo imaging of preclinical subjects, the M2 3D MR-based histology system is a portable, multimodal, and high-resolution MRI device. High-resolution 3D images of internal and anatomical morphology, as well as quantitative data on illness development and regression, are just a few of the many advantages of MRI that the M2 offers.
The Small Animal Imaging In Vivo market is categorized on the basis of technology and application. Based on technology, the market is segregated as Micro-MRI, Optical, Nuclear imaging, Micro-ultrasound. The application segment includes Cancer cell detection, Bio-distribution, Monitoring Therapy Response, Longitudinal Studies, Epigenetic Studies.
The optical segment category is expected to hold a major share in the global Small Animal Imaging In Vivo market in 2021. Since that operates quickly and simply and is more cost-effective than other modalities, optical imaging accounted for the highest revenue category. Due to features like precise and targeted operations that aid in producing better outcomes in preclinical research, micro-MRI technology is anticipated to see the greatest CAGR during the forecast period.
The two biggest application sectors are bio-distribution and tracking the treatment's effectiveness. The largest segment, bio-distribution, is anticipated to continue on its current trajectory during the projected period. In order to determine medication efficacy, optimize drug formulations, and identify acceptable profiles, drug-target engagement assessment of novel compounds or preclinical bio-distribution is essential. Non-invasive near-infrared (NIR) fluorescence imaging allows for real-time observation and detection of a new drug's bio-distribution across the entire body.
The region that brought in the most money was North America. Innovative modality innovations brought on by technological advancements are to blame for the market development in the area. Several preclinical studies conducted throughout the region are anticipated to aid the market's growth during the forecast period significantly. The presence of numerous producers of diagnostic devices, clinical research organizations, and pharmaceutical companies is expected to make Europe the second-largest market throughout the projection period. Due to the shifting of clinical research efforts from developed to developing countries, the Asia Pacific region is predicted to increase at the quickest rate during the projection period.
| Report Attribute | Specifications |
| Market size value in 2022 | USD 2.36 Bn |
| Revenue forecast in 2031 | USD 5.11 Bn |
| Growth rate CAGR | CAGR of 9.16 % from 2023 to 2031 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Technology and Application |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Bruker (US), General Electric (US), Koninklijke Philips N.V. (Netherlands), Hitachi Ltd. (Japan), Siemens Healthcare GmbH (Germany), FUJIFILM Corporation (Japan), Bruker (US), PerkinElmer Inc (US), Miltenyi Biotec (Germany), CMR Naviscan (US), SCANCO Medical AG (Switzerland), Aspect Imaging Ltd (Israel). |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Small Animal Imaging In Vivo Market By Technology-
Small Animal Imaging In Vivo Market By Application-
Small Animal Imaging In Vivo Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.